A novel variant of ileal bile acid binding protein is up-regulated through nuclear factor-κB activation in colorectal adenocarcinoma

Cancer Research

Volumn 67, Issue 19, 2007, Pages 9039-9046

  Fang, Changming ^a   Dean, Jarrod ^a   Smith, Jeffrey W ^a  

^a BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; DEOXYCHOLIC ACID; ILEAL BILE ACID BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CELL SURVIVAL; COLON ADENOCARCINOMA; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN VARIANT; RECTUM CARCINOMA; UPREGULATION;

ADENOCARCINOMA; AMINO ACID SEQUENCE; CACO-2 CELLS; CELL SURVIVAL; CHENODEOXYCHOLIC ACID; COLORECTAL NEOPLASMS; DEOXYCHOLIC ACID; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HUMANS; HYDROXYSTEROID DEHYDROGENASES; MOLECULAR SEQUENCE DATA; NF-KAPPA B; PROMOTER REGIONS (GENETICS); PROTEIN ISOFORMS; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 35148891241     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-3690     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30.
2. De la Chapelle A. Genetic predisposition to colorectal cancer. Nat Rev Cancer 2004;4:769-80.
3. Bernstein H, Bernstein C, Payne CM, Dvorakova K, Garewal H. Bile acids as carcinogens in human gastrointestinal cancers. Mutat Res 2005;589:47-65.
4. Debruyne PR, Bruyneel EA, Li X, Zimber A, Gespach C, Mareel MM. The role of bile acids in carcinogenesis. Mutat Res 2001;480-481:359-69.
5. McGarr SE, Ridlon JM, Hylemon PB. Diet, anaerobic bacterial metabolism, and colon cancer: a review of the literature. J Clin Gastroenterol 2005;39:98-109.
6. Bharti AC, Aggarwal BB. Nuclear factor-κB and cancer: its role in prevention and therapy. Biochem Pharmacol 2002;64:883-8.
7. Karin M. NF-κB and cancer: mechanisms and targets. Mol Carcinog 2006;45:355-61.
8. Yu YY, Li Q, Zhu ZG. NF-κB as a molecular target in adjuvant therapy of gastrointestinal carcinomas. Eur J Surg Oncol 2005;31:386-92.
9. Lind DS, Hochwald SN, Malaty J, et al. Nuclear factor-κB is upregulated in colorectal cancer. Surgery 2001;130:363-9.
10. Kojima M, Morisaki T, Sasaki N, et al. Increased nuclear factor-κB activation in human colorectal carcinoma and its correlation with tumor progression. Anticancer Res 2004;24:675-81.
11. Itzkowitz SH, Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol 2004;287:G7-17.
12. Cusack JC, Jr. Overcoming antiapoptotic responses to promote chemosensitivity in metastatic colorectal cancer to the liver. Ann Surg Oncol 2003;10:852-62.
13. Luo J-L, Kamata H, Karin M. IKK/NF-κB signaling: balancing life and death - a new approach to cancer therapy. J Clin Invest 2005;115:2625-32.
14. De Gottardi A, Touri F, Maurer CA, et al. The bile acid nuclear receptor FXR and the bile acid binding protein IBABP are differently expressed in colon cancer. Dig Dis Sci 2004;49:982-9.
15. Ohmachi T, Inoue H, Mimori K, et al. Fatty acid binding protein 6 is overexpressed in colorectal cancer. Clin Cancer Res 2006;12:5090-5.
16. Guttridge DC, Mayo MW, Madrid LV, Wang C-Y, Baldwin AS, Jr. NF-κB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science 2000;289:2363-6.
17. Gong YZ, Everett ET, Schwartz DA, Norris JS, Wilson FA. Molecular cloning, tissue distribution, and expression of a 14-kDa bile acid-binding protein from rat ileal cytosol. Proc Natl Acad Sci U S A 1994;91:4741-5.
18. Cacev T, Radosevic S, Spaventi R, Pavelic K, Kapitanovic S. NF1 gene loss of heterozygosity and expression analysis in sporadic colon cancer. Gut 2005;54:1129-35.
19. Chene L, Giroud C, Desgrandchamps F, et al. Extensive analysis of the 7q31 region in human prostate tumors supports TES as the best candidate tumor suppressor gene. Int J Cancer 2004;111:798-804.
20. Makishima M, Okamoto AY, Repa JJ, et al. Identification of a nuclear receptor for bile acids. Science 1999;284:1362-5.
21. Parks DJ, Blanchard SG, Bledsoe RK, et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 1999;284:1365-8.
22. Wang H, Chen J, Hollister K, Sowers LC, Forman BM. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol Cell 1999;3:543-53.
23. Grober J, Zaghini I, Fujii H, et al. Identification of a bile acid-responsive element in the human ileal bile acid-binding protein gene. Involvement of the farnesoid x receptor/9-cis -retinoic acid receptor heterodimer. J Biol Chem 1999;274:29749-54.
24. Hwang ST, Urizar NL, Moore DD, Henning SJ. Bile acids regulate the ontogenic expression of ileal bile acid binding protein in the rat via the farnesoid x receptor. Gastroenterology 2002;122:1483-92.
25. Kanda T, Foucand L, Nakamura Y, et al. Regulation of expression of human intestinal bile acid-binding protein in caco-2 cells. Biochem J 1998;330:261-5.
26. Yui S, Saeki T, Kanamoto R, Iwami K. Characteristics of apoptosis in HCT116 colon cancer cells induced by deoxycholic acid. J Biochem (Tokyo) 2005;138:151-7.
27. Nagengast FM, Grubben MJ, van Munster IP. Role of bile acids in colorectal carcinogenesis. Eur J Cancer 1995;31:1067-70.
28. Reddy BS, Mastromarino A, Wynder EL. Further leads on metabolic epidemiology of large bowel cancer. Cancer Res 1975;35:3403-6.
29. Shah SA, Volkov Y, Arfin Q, Abdel-Latif MM, Kelleher D. Ursodeoxycholic acid inhibits interleukin β1 and deoxycholic acid-induced activation of NF-κB and AP-1 in human colon cancer cells. Int J Cancer 2006;118:532-9.
30. Shishodia S, Aggarwal BB. Guggulsterone inhibits NF-κB and IκBα kinase activation, suppresses expression of anti-apoptotic gene products, and enhances apoptosis. J Biol Chem 2004;279:47148-58.
31. Gilmore TD, Herscovitch M. Inhibitors of NF-κB signaling: 785 and counting. Oncogene 2006;25:6887-99.